| 370 | 3 | 255 |
| 下载次数 | 被引频次 | 阅读次数 |
目的采用高效液相色谱-串联质谱(LC-MS/MS)法建立同时检测人血浆中奥氮平与拉莫三嗪浓度方法。方法以Agilent Eclipse plus C18(100 mm×4.6 mm,5μm)为分析柱,流动相为含5 mmol·L-1甲酸铵的甲醇-水体系(75∶25),流速为0.5 m L·min-1,以奥氮平-D3及拉莫三嗪-13C3-D3为内标,采用蛋白沉淀法进行样本处理,采用选择性离子监测(MRM),通过三重四级杆串联质谱仪正离子模式同时分析奥氮平(m/z 313→256)与拉莫三嗪(m/z 256→145)血浆浓度,并应用于检测46份临床样本。结果奥氮平在2~200μg·L-1(R2=0.997 2)内线性较好,高、中、低浓度质控日内(n=6)及日间(n=3)精密度RSD值均低于7.13%,准确度在97.47%~102.70%内,提取回收率为94.24%,103.31%,102.28%;拉莫三嗪在0.2~25 mg·L-1(R2=0.998 8)内线性较好,高、中、低浓度日内(n=6)及日间(n=3)精密度RSD值均低于5.56%,准确度在93.97~102.55%内,提取回收率为100.89%、93.66%、91.27%。结论本方法可简便、灵敏、高效测定人血浆中奥氮平与拉莫三嗪血药浓度且特异性好,人血浆内源性杂质不干扰奥氮平和拉莫三嗪的测定。
Abstract:AIM To develop an LC-MS /MS method for simultaneous determination of olanzapine and lamotrigine in human plasma. METHODS Agilent Eclipse plus C18column( 100 mm × 4. 6 mm,5 μm) was used to separate the analytes,and the mobile phase was methanol-water( 75∶ 25) system containing with 5 mmol·L- 1ammonium format at a flow rate of 0. 5 m L·min- 1. The olanzapine-D3 and lamotrigine-13C3-D3 were employed as the internal standard,and the human plasma sample was precipitated by methanol. Simultaneously detecting the plasma drug concentration of olanzapine( m / z 313→256) and lamotrigine( m / z 256→145) was performed with multiple reactions monitoring( MRM) using positive eletrospray ionization( ESI) by triple quadrupole mass spectrometer. RESULTS The calibration curves for olanzapine had good linearity( R2= 0. 997 2,n = 7) within the range of 2- 200μg·L- 1. The high,medium and low concentration RSD of inter- and intra-day precisions were less than 7. 13%and accuracy was between 97. 47% and 102. 70%. The extraction recoveries of olanzapine were 94. 24%,103.31% and 102. 28%,respectively. The linear calibration curve of lamotrigine had good linearity( R2= 0. 998 8,n =7) within the range of 0. 2- 25 mg·L- 1. The high,medium and low concentration RSD of inter- and intra-day precisions were less than 5. 56% and accuracy was within 93. 97%- 102. 55%. The extraction recoveries of olanzapine were 100. 89%,93. 66% and 91. 27% respectively. CONCLUSION This method is simple,sensitive and efficient to simultaneously detect olanzapine and lamotrigine in human plasma with good specificity,and the internal impurity doesn't interfere with the simultaneously determination of olanzapine and lamotrigin.
[1]Erickson-Ridout KK,Zhu J,Lazarus P.Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants[J].Pharmacogenet Genomics,2011,21(9):539.
[2]Domingues DS,Pinto Mal,De Souza ID,et al.Determination of drugs in plasma samples by high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring of schizophrenic patients[J].J Anal Toxicol,2016,40(1):28.
[3]Hiemke C,Baumann P,Bergemann N,et al.AGNP consensus guidelines for therapeutic drug monitoring in psychiatry:update2011[J].Pharmacopsychiatry,2011,44(6):195.
[4]Kobylinska K,Bus KM,Bukowska-Kiliszek M.A high performance liquid chromatography with electrochemical detection for the determination of olanzapine inhuman plasma[J].Acta Pol Pharm,2008,65(6):759.
[5]Zheng Q,Wang F,Li H,et al.Quantitative analysis of olanzapine in rat brain microdialysates by HPLC-MS/MS coupled with columnswitching technique[J].J Chromatogr B Analyt Technol Biomed Life Sci,2012,905:127.
[6]Bonde SL,Bhadane RP,Gaikwad A,et al.Simultaneous determination of olanzapine and fluoxetine in human plasma by LC-MS/MS:Its pharmacokinetic application[J].J Pharm Biomed Anal,2014,90:64.
[7]Saracino MA,Koukopoulos A,Sani G,et al.Simultaneous high performance liquid chromatographic determination of olanzapine and lamotrigine in plasma of bipolar patients[J].Ther Drug Monit,2007,29(6):420.
[8]温预关,廖日房,王伟华.LC-ESI-MS/MS快速测定人血浆中奥氮平的浓度及临床应用[J].中国药学杂志,2009,44(23):1815.
[9]和凡,温预关,杨彤,等.LC-MS/MS法测定癫痫患儿血浆中拉莫三嗪的浓度[J].今日药学,2011,21(3):154.
[10]国家药典委员会中华人民共和国药典:四部[S].北京:化学工业出版社,2015:363-367.
基本信息:
DOI:10.19577/j.cnki.issn10074406.2016.05.004
中图分类号:R969;O657.63
引用信息:
[1]黄文灿,倪晓佳,卢浩扬,等.LC-MS/MS法同时检测人血浆中奥氮平与拉莫三嗪浓度[J],2016,25(05):278-282.DOI:10.19577/j.cnki.issn10074406.2016.05.004.
基金信息:
国家自然科学基金(编号81403016);; 广州市医药卫生科技项目(编号20141A011041);; 广东省自然科学基金(编号2015A030313808)
2016-02-15
2016
2016-05-26
2016
1